Clarivate (CLVT) Q3 2026 Earnings
Adjusted figure includes LS&H (discontinued operations). GAAP diluted EPS was $(0.13), including a $62.2 million non-cash LS&H goodwill impairment and a $10.1 million loss on classification as held for sale.
How Did CLVT Stock React to Q3 2026 Earnings?
Did CLVT Beat Earnings? Q3 2026 Results
Yes. Clarivate reported Q3 2026 earnings of $0.21 a share on Nov 3, 2026, beating the $0.16 consensus estimate by 32.1%. Revenue was $481.6M against a $490.1M estimate.
Clarivate Plc delivered a sharply mixed third quarter of 2026, beating Wall Street's earnings expectations by a wide margin while falling short on revenue, extending its streak of consensus EPS beats to six consecutive quarters. The information services company reported adjusted diluted EPS of $0.21, clearing the $0.16 consensus estimate by 32.08%, even as revenue of $481.60 million trailed the $490.10 million consensus by 1.73% and slid 22.7% year over year. The primary driver of both the headline revenue decline and the earnings complexity was portfolio reshaping: Clarivate completed the sale of its Life Sciences and Healthcare segment on October 6 for net cash proceeds of $488.40 million, with LS&H now classified as discontinued operations and excluded from the continuing business. Stripping out those effects, organic revenue on a continuing-operations basis rose 0.4%, with subscription revenue up 1.5%. GAAP results reflected a $62.20 million non-cash goodwill impairment tied to LS&H. Looking ahead, management guided full-year 2026 revenue to $1.97 billion to $1.99 billion and adjusted diluted EPS of $0.73 to $0.77, with fourth-quarter recurring organic growth expected to accelerate to 2.00% to 2.50%.
- Organic subscription growth of 1.5% from new sales and pricing actions
- Organic re-occurring growth of 0.7% from higher IP volumes
- Return to positive ACV growth in Intellectual Property segment
- Organic ACV growth of 1.8% driven by improved product pricing
- Transactional revenue decline from A&G product group wind-downs and migration to subscription products
- Inorganic disposals reduced reported revenue
- $62.2 million non-cash LS&H goodwill impairment drove wider GAAP net loss
- Lower interest expense from debt reduction
“Third quarter results continued to improve across key metrics, including organic recurring revenue growth and the return to positive ACV growth in the Intellectual Property segment.”
Clarivate CEO, on the earnings call
What Is Clarivate's Outlook?
Updated 2026 outlook excludes discontinued operations (LS&H) from Q4 and assumes no further acquisitions, divestitures or unanticipated events. Full year 2026: - ACV organic growth of 1.75%–2.25% - Recurring organic revenue growth of 1.00%–1.50% - Revenues of $1.965B–$1.985B - Adjusted EBITDA of $0.865B–$0.885B (43.0%–45.0% margin) - Adjusted diluted EPS of $0.73–$0.77 - Free cash flow of $320M–$340M Q4 2026: - ACV organic growth of 1.75%–2.25% - Recurring organic revenue growth of 2.00%–2.50% - Revenues of $490M–$510M - Adjusted EBITDA of $215M–$235M (44.0%–46.0% margin) - Adjusted diluted EPS of $0.14–$0.18 - Free cash flow of $85M–$105M The EPS outlook assumes about 646 million fully diluted adjusted shares.
CLVT YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $481.6M | $623.1M | −22.7% |
| Operating Income | $40.1M | $44.0M | −8.9% |
CLVT Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.